Interleukin Genetics Inc. is touting a study it says shows the efficacy of its weight management genetic test.
Genomics/Molecular Diagnostics
PrimeraDx lands $20 million Series C round
PrimeraDx Inc. drummed up another hefty chunk of change, raising $20 million in a Series C round from new and existing investors.
The Marlborough, Mass.-based molecular diagnostics maker said a new backer, CHL Medical Partners, led the round and was joined by previous backers including Abingworth, InterWest Partners, Malaysian Technology Development Corp., MPM Capital, Burrill & Co. and the Invus Group.
Millipore plans more work with Gen-Probe spinoff
Billerica, Mass.-based Millipore Corp. plans to keep working on molecular assays and portable instruments for biopharmaceutical production with a brand new company, following its spinout from Gen-Probe Inc.
PerkinElmer acquires Asian genetic screening, diagnostics businesses
PerkinElmer Inc. expanded its reach in Asia, acquiring an Indian genetic testing firm for an undisclosed amount and spending $64 million on a Shanghai-based diagnostic supplies provider.
The Waltham, Mass.-based devices and diagnostics giant said it bought Chennai, India-based Surendra Genetic Labs Pvt Ltd., which provides testing services for pregnant mothers and newborns.
The purchase will be folded into PerkinElmer’s genetic screening business, according to division president Ann-Christine Sundell.
PrimeraDx lands $1 million in debt round
Primera Biosystems Inc. landed $1.15 million in a debt financing round, according to a filing with the federal Securities and Exchange Commission.
The Mansfield, Mass.-based molecular diagnostics maker, which is developing a nucleic acid analysis system it calls Scalable Target Amplification Routine — STAR — last raised $21 million in a Series B equity round early last year.
UPDATE: IntelligentMDx is ahead of schedule in developing its new Swine Flu test
IntelligentMDx announced that it’s developed an assay solution for influenza that can distinguish seasonal strains from the H1N1 variant, better known as the Swine Flu.
The company said the assay will be available during the autumn flu season and was designed to comply with Food & Drug Administration and other regulatory guidelines.
IntelligentMDx spokeswoman Elizabeth Holland wrote in an email that the test can also detect a patient’s potential resistance or susceptibility to anti-viral medications.
AdvanDx drums up $8 million
AdvanDx drummed up an $8 million Series C funding round from a pair of its existing investors.
The Woburn, Mass.-based molecular diagnostics maker said SLS Venture and LD Pensions ponied up the cash, which the company intends to put toward expanding its product offering and boost its international sales and marketing push.
AdvanDx also said its shareholders elected Tina Christensen, vice president and CFO of Danish health insurance company IHI danmark, to its board of directors.
Q2 sales, net losses grow for Exact Sciences
Exact Sciences Corp. got big sales boost during the second quarter, but net losses still widened as the colorectal cancer screening firm settling into its new digs in Wisconsin and started paying the vig on a licensing deal with the Mayo Clinic.
Madison, Wis.-based Exact Sciences posted a net loss of $2.4 million on sales of $1.3 million during the three months ended June 30, compared with a net loss of $2.1 million on negative revenues of $146,000 during the same period last year.
Interleukin Genetics’ Q2 sales fall, net losses rise
Interleukin Genetics Inc. posted declines to both its top and bottom lines during the second quarter, as the genetic test maker shed a non-core business to focus on a new weight gain risk diagnostic.
Waltham, Mass.-based Interleukin reported sales of $223,000 for the three months ended June 30, down 57.3 percent compared with $522,000 during the same period last year.
MassDevice Q&A: John McDonough
John McDonough, CEO of Cambridge, Mass.-based T2 Biosystems Inc., is an optimist.
Bullish on his 22-employee company’s prospects (the estimated $40 billion diagnostics market might have something to do with that), McDonough (far left in the picture at right) spoke with MassDevice about the technology behind T2’s diagnostic device, which uses a miniaturized version of a magnetic resonance imaging machine to deliver near-instant test results from just about any blood, urine or saliva sample.
First Swine Flu test nod goes to Quest Diagnostics
The race to be the first to get a diagnostic test for Swine Flu to market tipped to Quest Diagnostics, after the Food & Drug Administration gave emergency use authorization to one of its subsidiary’s H1N1 influenza virus tests.